TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Represents approximately US$500,000 in potential minimum purchases over the initial term and targets growing demand for medication temperature protection across insulin, GLP-1 therapies, biologics and other injectable medications
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd.

